Simian immunodeficiency virus (SIV) infection in macaques represents a widely used, non-human primate model to study pathogenic lentivirus infection and to evaluate new therapeutic strategies against human immunodeficiency virus (HIV). In live-attenuated SIV vaccination (LAV) studies, significant levels of protection against wildtype virus challenge can be conferred against both homologous (Almond et al., 1995; Berry et al., 2008; Daniel et al., 1992) and heterologous Wyand et al., 1999) virus challenge. However, levels of protection vary between different viral challenges and among different host species. Although a live-attenuated HIV vaccine is unlikely ever to be employed due to safety concerns, characterization of the mechanism of protection could unveil novel strategies to reproduce this potent protection safely. In the Mauritian cynomolgus macaque (Macaca fascicularis; MCM) model, protection seems to be acting as early as 21 days post-vaccination (Stebbings et al., 2004; Berry et al., 2011) , when adaptive responses are either not fully matured or do not appear to be central to the protection observed in this model (Almond et al., 1997; Stebbings et al., 2005) .
To extend these studies, we examined whether TRIM5a expression is induced by live-attenuated SIV vaccination and whether TRIM5a polymorphism may play a contributory role in vaccine outcome. TRIM5a is a component of the innate immune system responsible for an intracellular block to retroviruses (Stremlau et al., 2004; Yap et al., 2004) , as well as being a sensor for the innate immune response (Pertel et al., 2011) . In SIV/macaque studies, polymorphisms in TRIM5a have been correlated with differential control of SIV infection (de Groot et al., 2011; Kirmaier et al., 2010; Lim et al., 2010) , suggesting that genotypic variation in TRIM5a and/or expression may impact both on the ability of an attenuated SIV to replicate in vivo and, perhaps, on subsequent protection conferred by live-attenuated SIV vaccination. However, expression levels of TRIM5a in tissues susceptible to SIV infection have not been hitherto described. Here, we have measured TRIM5a mRNA levels in a previously reported earlypathogenesis SIV/MCM study (Li et al., 2011) . Briefly, 16 MCM were inoculated intravenously with a nef-disrupted SIV, SIVmac251/C8, which has been shown to confer protection at 3 and 20 weeks post-infection (Berry et al., , 2008 Stebbings et al., 2004) . At these and earlier time points, macaques were sacrificed and multiple lymphoid tissues and blood were collected. Viral RNA (vRNA) in plasma was detected at day 3, increasing progressively to a peak at day 10; vRNA then declined, but still persisted at low levels at day 125 (Li et al., 2011) . Total RNA was isolated from a range of different tissues taken at 0, 3, 7, 10, 21 and 125 days post-inoculation, and TRIM5a and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA levels were quantified by SYBR Greenbased quantitative PCR, using primers TRIM5s (59-C-GCTACTGGGTTGATGTGACAC-39) and TRIM5ns (59-CCCTGGTGCCTGATACATTATCTG-39) or GAPDH-s (59-G-GCTGAGAACGGGAAGCTC-39) and GAPDH-ns (59-AGGGATCTCGCTCCTGGAA-39). TRIM5a copy number was normalized to that of GAPDH and expressed as fold difference in comparison to one of the naïve animals (A1; Fig. 1 ). Despite considerable variation across individual tissues and between vaccinates in response to SIVmac251/C8 infection, there was a significant increase in TRIM5a mRNA expression over days 3, 7 and 10, when all tissues were analysed together and compared with naïve, unvaccinated macaques (P50.012, two-tailed t-test). However, beyond the peak of virus production (day 10), TRIM5a mRNA expression returned to the normal range between days 21 and 125, when the plasma viral RNA levels were low, and the overall virus profile is that of a controlled infection. TRIM5a mRNA kinetics were similar to those observed previously for APOBEC3G in rhesus macaques (Mußil et al., 2011) , suggesting a general response to acute retroviral infection, most likely mediated by a type 1 interferon. Whether this increase in restriction factor expression levels influences the antiviral state of the host is difficult to determine, as the transient increase in TRIM5 mRNA levels was not maintained at these higher induction levels beyond the immediate acute phase, and no correlation was found between TRIM5a expression and viral load in plasma (Fig. 1) . However, we reasoned that the higher level of TRIM5a expression observed during the peak of primary viraemia could influence subsequent outcome of SIV infection or vaccination, the extent of which could differ in MCM with different TRIM5a genotypes. A17  A16  A15  A14  A13  A12  A11  A10  A9  A8  A7  A6  A5  A4  A3  A2  A1 Fig. 1. TRIM5a RNA expression level in tissues. Total RNA was extracted from cell-derived tissues and reverse-transcribed, and cDNA equivalent to 20-50 ng total RNA was used in a SYBR Green-based quantitative PCR. PCR product specificity was assessed by dissociation curves. TRIM5a copy numbers were normalized to 5¾10 5 GAPDH copies and the naïve animal A1, used as calibrator. All experiments were run in duplicate and error bars represent the mean±SD of two independent experiments. vRNA in plasma for each animal at the time of termination (X) was measured by quantitative RT-PCR as described previously (Berry et al., 2008) .
In rhesus macaques (Macaca mulatta), variations in the sequence of the TRIM5a B30.2 domain, including its replacement with cyclophilin A, have a great impact on lentiviral infection both in vivo and in vitro (de Groot et al., 2011; Kirmaier et al., 2010; Lim et al., 2010; Wilson et al., 2008) . MCM display limited genetic diversity as a result of a small founder population and geographical isolation (Tosi & Coke, 2007) , offering the potential to develop an SIV/macaque model where the confounding effects of host genetics can be minimized. TRIM5a genotypes in cynomolgus macaques of different origin have also been recently characterized (Berry et al., 2012; de Groot et al., 2011; Dietrich et al., 2011; Saito et al., 2012) . Only three alleles have been identified in MCM: mafa-4 (identical to rhesus mamu-4) and cynomolgus-specific mafa-8 and mafa-9, but to date no TRIMCyp variants (with cyclophilin A) have been identified (Berry et al., 2012; de Groot et al., 2011; Dietrich et al., 2011) . These three alleles, in the B30.2 domain, differ only by three amino acids (M330V and Y389C in mafa-8, and I437V in mafa-9); however, they all share the Q339TFP polymorphism, which, in rhesus macaques, is associated with a permissive phenotype (Kirmaier et al., 2010; Lim et al., 2010) . We extended this genotyping of MCM as described previously (Berry et al., 2012) to a total of 90 MCM. This confirmed the presence of only the three previously identified alleles, with the mafa-4/4 homozygote constituting 56.7 % of the population, and with only four of 90 MCM not carrying the mafa-4 allele (Fig. 2a) .
We then examined the contribution of each genotype to the level of plasma vRNA at the time of peak viraemia (10-14 days) Six of eight animals challenged with SIVsmE660 and three of eight animals infected with SIVmac251/L28 were protected. One of the two SIVsmE660-superinfected animals and two with SIVmac251/L28 were vaccinated for 3 weeks and the others for 20 weeks. MCM were grouped based on study outcome and compared with the whole population. Percentages of each genotype [mafa-4/4 (black), -4/8 (white), -4/9 (grey) and -8/9 (striped)] were calculated for each group. Distribution of the genotypes among the different groups was not found to be statistically significantly different as assessed by Fisher's exact test.
following intravenous infection with 5000 TCID 50 of the 9/ 90 pool of SIVmacC8 (Rud et al., 1994) as used in liveattenuated SIV vaccine studies, or 10-10 000 MID 50 of an uncloned heterologous SIVsmE660 challenge stock , representing a wild-type SIVsm-derived virus (Fig. 2b, c) . No major differences in viral load at the peak of viraemia for SIVmacC8 could be associated with any of the TRIM5a genotypes (Fig. 2b) . Levels of SIVsmE660 in plasma were also similar, regardless of the initial viral dose or TRIM5a genotype (Fig. 2c) , although the difference in the mean for the mafa-4/4 homozygotes and the mafa-4/9 heterozygotes was significant by Dunn's multiple comparison test. Hence, there was no strong impact of TRIM5a genotype on acquisition or replication potential of SIVmac or SIVsm in vivo in MCM.
In further support of this hypothesis, we retrospectively analysed two previously published LAV vaccination studies. Briefly, 16 MCM were vaccinated with 5610 3 TCID 50 SIVmacC8 and challenged with either SIVmac251/L28 (Berry et al., 2008) or SIVsmE660 , representing homologous and heterologous challenges, respectively. Taking these two vaccine populations together, irrespective of the composition of the virus challenge, mafa-4/4 homozygotes constituted 62.5 % of the protected macaques, 50 % of the superinfected and 55.8 % of the total; mafa-4/8 heterozygotes were slightly more represented in the superinfected (a) Cell lysates were harvested 2 weeks post-TRIM5a expression, after selection with G418, and subjected to immunoblotting using monoclonal anti-HA.11 antibody. b-Actin was detected on the same membrane to assess protein input. (b) CRFK cells were infected with fivefold serial dilutions of GFP-expressing lentiviruses and viral titres were determined by monitoring EGFP expression by flow cytometry. Histograms represent the mean±SEM of three independent experiments. Only for HIV-1 was the reduction of viral titre between empty vector (EV) and MCM TRIM5a alleles statistically significant (t-test; P,0.05).
MCM (28.6 %) than in protected ones or the whole population (18.6 and 18.7 %, respectively). A total of 18.7 % of the protected macaques, 14.3 % of the superinfected and 20 % of all MCM were mafa-4/9 heterozygotes. There was just one macaque with the genotype mafa-8/9, which was protected from viral rechallenge, but there were insufficient data for statistical analysis. These data suggest that distribution of TRIM5a genotypes among vaccine study populations does not differ significantly between protected and superinfected vaccinated macaques, in comparison with the whole population (Fig. 2d) , and hence TRIM5a genotype per se has no impact on vaccine/study outcome. This would appear to hold for both homologous and heterologous virus challenges in such a scenario.
Finally, the three MCM TRIM5a alleles were tested in vitro for their ability to restrict lentiviral infection. TRIM5a genes were PCR-cloned using cDNA from animals with genotypes mafa-4/8 and mafa-4/9 and the following primers: sense, 59-TAGAATTCGCTTCTGGAATCCTGC-39, and antisense, 59-TCACGTCGACTCAAGAGCTTGG-TGAG-39 (EcoRI and SalI restriction sites underlined). PCR products were subcloned into the gammaretroviral vector EXN (Zhang et al., 2006) , downstream and in frame with a haemagglutinin (HA) tag using the restriction enzymes EcoRI and SalI. Crandell-Rees feline kidney (CRFK) cells stably expressing TRIM5a alleles were produced as described previously (Ylinen et al., 2010) . Similar TRIM5a expression levels were assessed by Western blotting using an anti-HA.11 antibody (Covance; dilution 1 : 1000) and anti-b-actin (Abcam; dilution 1 : 1000), together with an HRP-conjugated anti-mouse IgG antibody (DAKO; 1 : 3000 dilution) (Fig. 3a) . TRIM5a-expressing cells were exposed to serial dilutions of VSV-G-pseudotyped, lentiviral vectors derived from HIV-1 (Zufferey et al., 1997) , HIV-2 (Griffin et al., 2001) or SIVmac251 (Nègre et al., 2000) carrying a GFP marker gene, and infectious titres were inferred by flow-cytometry analysis. GFP/SIVsmE660 was obtained by replacing SIVmac Gag aa 1-373 with the equivalent residues from SIVsmE660, using XhoI and AgeI restriction sites added to the SIVmac packaging plasmid SIV3+ by mutagenesis. The SIVsmE660 gag sequence (GenBank accession no. JX119100) was cloned from vRNA purified from infected animals using the following primers: sense, 59-TAGAGCTCGAGATGGGCGCGAGAAACTCCGT-C-39, and antisense, 59-TCGCGACCGGTCTCAGTGCCTCT-TTCAATGCTTC-39 (XhoI and AgeI restriction sites underlined). As expected, HIV-1 vector titre was reduced in cells expressing the simian TRIM5a genes, but no significant reduction of titre was observed for HIV-2, SIVmac251 or SIVsmE660 (Fig. 3b) . The non-restrictive phenotype of the MCM TRIM5a alleles, which all carry a glutamine at aa 339, concurs with previous reports (Kirmaier et al., 2010; Lim et al., 2010; Wilson et al., 2008) .
Although we cannot categorically exclude a contribution of TRIM5a gene expression to the long-term control of SIV/ HIV-2 infection in vivo and/or vaccination in MCM, we hypothesize that any effects will be minimal, as the only three alleles identified in MCM do not restrict HIV-2, SIVmac251 or SIVsmE660 (Fig. 3) . In addition, no correlation between the four different MCM TRIM5a genotypes and outcome of SIV infection in naïve or vaccinated MCM was observed, although a larger number of animals could improve the statistical significance of these observations. MHC genotyping will still be required, as it has been shown that certain MCM haplotypes have an impact on SIV infection in MCM (Mee et al., 2009; Mühl et al., 2002) . Animals used in this study have been MHCgenotyped and only two of them (A5 and A17) express allele M6, associated with spontaneous control of infection.
No correlation was found with virus replication (Fig. 1) .
The results presented here suggest that prerequisite TRIM5a genotyping is of low priority in cynomolgus macaques of Mauritian origin. Our data consolidate the MCM/SIV system as a powerful model to study HIV/AIDS, where bias introduced by host genetics can be reduced to a minimum and rationalized. The replication potential of different SIVmac/SIVsm viruses appears to be largely unimpeded by different TRIM5 genotypes in this non-human primate model of HIV infection and study outcomes unaffected by predisposition to particular TRIM5 variants.
